Literature DB >> 33203697

Macrophage-Based Approaches for Cancer Immunotherapy.

Nicholas R Anderson1, Nicholas G Minutolo1, Saar Gill2, Michael Klichinsky3.   

Abstract

Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in hematologic malignancies, but its application to solid tumors has proven challenging. This gap has spurred the investigation of alternative immune cells as therapeutics. Macrophages are potent immune effector cells whose functional plasticity leads to antitumor as well as protumor function in different settings, and this plasticity has led to notable efforts to deplete or repolarize tumor-associated macrophages. Alternatively, macrophages could be adoptively transferred after ex vivo genetic modification. In this review, we highlight the role of macrophages in solid tumors, the progress made with macrophage-focused immunotherapeutic modalities, and the emergence of chimeric antigen receptor macrophage cell therapy. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 33203697     DOI: 10.1158/0008-5472.CAN-20-2990

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  68 in total

Review 1.  Myeloid cell-targeted therapies for solid tumours.

Authors:  Sangeeta Goswami; Swetha Anandhan; Deblina Raychaudhuri; Padmanee Sharma
Journal:  Nat Rev Immunol       Date:  2022-06-13       Impact factor: 53.106

Review 2.  Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.

Authors:  Handi Cao; Ryohichi Sugimura
Journal:  Cancer Treat Res       Date:  2022

3.  IgD ligation allows peritoneal cavity B cell proliferation.

Authors:  Jennifer Londregan; Jeffrey Maslanka; Naomi Goldman; John Somerville; James E Riggs
Journal:  Immunobiology       Date:  2022-01-20       Impact factor: 3.144

Review 4.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 5.  Empowering patients from within: Emerging nanomedicines for in vivo immune cell reprogramming.

Authors:  Matthias T Stephan
Journal:  Semin Immunol       Date:  2021-11-26       Impact factor: 11.130

6.  Cytokine/Chemokine Release Patterns and Transcriptomic Profiles of LPS/IFNγ-Activated Human Macrophages Differentiated with Heat-Killed Mycobacterium obuense, M-CSF, or GM-CSF.

Authors:  Samer Bazzi; Emale El-Darzi; Tina McDowell; Helmout Modjtahedi; Satvinder Mudan; Marcel Achkar; Charles Akle; Humam Kadara; Georges M Bahr
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 7.  Cord-Blood-Derived Professional Antigen-Presenting Cells: Functions and Applications in Current and Prospective Cell Therapies.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 8.  Pro-Tumorigenic Macrophage Infiltration in Oral Squamous Cell Carcinoma and Possible Macrophage-Aimed Therapeutic Interventions.

Authors:  Flavia Bruna; Pablo Scodeller
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

Review 9.  Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.

Authors:  Saghar Pahlavanneshan; Ali Sayadmanesh; Hamidreza Ebrahimiyan; Mohsen Basiri
Journal:  J Immunol Res       Date:  2021-05-22       Impact factor: 4.818

Review 10.  Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.

Authors:  Hao Cai; Yichi Zhang; Jian Wang; Jinyang Gu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.